Pharmaceutical Video Marketing Playbook for Mumbai Teams

01

What is different about pharmaceutical

Pharma and life sciences companies communicating to doctors, regulators and patients. That shapes everything downstream. The buying decision in this sector is rarely made by one person in one sitting, which means a single hero film is almost never the right first investment — a set of shorter, purpose-built assets mapped to stages of the decision outperforms it consistently.

MCI and DCGI-safe messaging, no unapproved indication claims. Treating that as a production constraint rather than an afterthought is what separates a schedule that holds from one that slips: we route the script through the compliance reviewer before production begins, and keep a claims-substantiation sheet alongside it so every on-screen statement has a source.

The second difference is vocabulary. Pharmaceutical audiences detect generic corporate language instantly, and it costs credibility in the first ten seconds. Scripts here are written with someone who actually works in the function, not adapted from a template.

02

The asset stack, in build order

Teams that get value from video build in sequence rather than commissioning a flagship film and hoping it works everywhere. The order below is the one we recommend to pharmaceutical clients: start with the asset that removes the biggest objection, then the one that explains, then the one that builds preference.

Each of these is a distinct brief with a distinct metric. Bundling them into one film is the most common and most expensive mistake in the sector, because a single asset asked to do three jobs does none of them well and cannot be evaluated against any of them.

03

Use cases that consistently earn their budget

Across pharmaceutical clients the same handful of applications keep returning a measurable result. Each one below is briefed, scripted and delivered as a distinct asset rather than as a cutdown of something else — the cutdown approach is why so much sector video underperforms.

• MR detailing films — scoped as a standalone asset with its own script, metric and distribution plan.
• Plant and GMP walkthroughs — scoped as a standalone asset with its own script, metric and distribution plan.
• Patient education — scoped as a standalone asset with its own script, metric and distribution plan.
• Congress films — scoped as a standalone asset with its own script, metric and distribution plan.

04

Getting it through compliance without gutting it

MCI and DCGI-safe messaging, no unapproved indication claims. The instinct is to write safe and hope the reviewer waves it through. That produces films nobody watches. The better route is to write the strong version, then substantiate every claim in it, so the compliance conversation is about evidence rather than tone.

Practically: a claims sheet accompanies the script, mapping each on-screen statement to its source. Review happens at script stage and again at fine cut, with the same reviewer. Two checkpoints, both dated in the schedule. We have never seen a project fail compliance late when both were held.

05

Budget planning across a year

Sector teams almost always get better value from an annual plan than from project-by-project commissioning. Batching two or three films into a single production block shares the pre-production, crew mobilisation and setup cost across all of them, which typically saves 20 to 30 per cent against commissioning the same films separately over a year.

An annual plan also fixes the versioning problem. When the full asset list is known up front, cutdowns and language versions are scoped and priced at the start rather than requested individually at a premium.

06

How to measure whether it worked

Most video budgets in Mumbai are approved without a success metric, which is why the second film is always harder to get signed off than the first. Decide the number before production starts and instrument for it: view-through rate at 25, 50 and 75 per cent tells you where the script loses people; click-through and assisted conversions tell you whether the proposition landed; and for internal work, completion rate against a training or onboarding cohort is the only figure that matters.

Set the benchmark honestly. A pharmaceutical video asset placed on a landing page above the fold behaves nothing like the same cut running as paid social, and comparing the two produces a false conclusion. We publish expected ranges with the delivery so the marketing team is not benchmarking a 90-second explainer against a six-second bumper.

Review at 30 days, not at launch week. The first week's numbers are dominated by internal traffic and paid burst spend. The 30-day picture is what tells you which cutdown to fund next, which thumbnail to replace, and whether the opening ten seconds needs a re-edit — a cheap fix that regularly doubles retention without a reshoot.

07

Where these projects go wrong

Failed video projects in Mumbai rarely fail on craft. They fail on decisions made before anyone picked up a camera — an unclear owner, a brief written as a format, a review chain nobody mapped. The pattern is consistent enough that we plan against it explicitly, and it is worth checking your own project against the same list before you commission anything.

The most expensive of these is the late approver. A stakeholder who appears at fine cut with a structural objection is not asking for a revision, they are asking for a reshoot, and by then the crew is on another job and the location is booked out. Naming one arbiter at kickoff is free and saves more money than any negotiation on day rates.